Evidence map›Paper›PMID 40272409›Full record

ArticleeLife2025

Stabilization of GTSE1 by cyclin D1-CDK4/6-mediated phosphorylation promotes cell proliferation with implications for cancer prognosis.

Nelson García-Vázquez, Tania J González-Robles, Ethan Lane, Daria Spasskaya, Qingyue Zhang, Marc A Kerzhnerman, YeonTae Jeong, Marta Collu, Daniele Simoneschi, Kelly V Ruggles and 3 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Nelson García-VázquezDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.
Tania J González-RoblesDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.ORCID https://orcid.org/0000-0001-9292-382X
Ethan LaneDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.
Daria SpasskayaDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.
Qingyue ZhangDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.
Marc A KerzhnermanDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.
YeonTae JeongDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.
Marta ColluDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.
Daniele SimoneschiDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.ORCID https://orcid.org/0000-0003-0448-4295
Kelly V RugglesDepartment of Medicine, New York University Grossman School of Medicine, New York, United States.ORCID https://orcid.org/0000-0002-0152-0863
Gergely RónaDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.
Sharon KaisariDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.ORCID https://orcid.org/0000-0002-6884-3886
Michele PaganoDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, United States.ORCID https://orcid.org/0000-0003-3210-2442

Funding

Training Program in Cell BiologyT32GM136542 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SMITH, SUSAN · 2020 to 2024
$3.0M
Regulation of the cell proliferation by CRL ubiquitin ligases-diversity supplementR35GM136250 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICHELE PAGANO · 2020 to 2026
$2.7M
Howard Hughes Medical Institute GT15758NIGMS NIH HHS R35 GM136250NIGMS NIH HHS T32 GM136542NIH HHS GM136250NIH HHS T32GM136542
6 · The paper itself

Abstract

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers. The cancer-related function of cyclin D1 has been primarily studied by focusing on the phosphorylation of the retinoblastoma (RB) gene product. Here, using an integrative approach combining bioinformatic analyses and biochemical experiments, we show that GTSE1 (G-Two and S phases expressed protein 1), a protein positively regulating cell cycle progression, is a previously unrecognized substrate of cyclin D1-CDK4/6 in tumor cells overexpressing cyclin D1 during G1 and subsequent phases. The phosphorylation of GTSE1 mediated by cyclin D1-CDK4/6 inhibits GTSE1 degradation, leading to high levels of GTSE1 across all cell cycle phases. Functionally, the phosphorylation of GTSE1 promotes cellular proliferation and is associated with poor prognosis within a pan-cancer cohort. Our findings provide insights into cyclin D1's role in cell cycle control and oncogenesis beyond RB phosphorylation.

Indexed as

Cell ProliferationCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6NeoplasmsCell Line, TumorHumansPhosphorylationPrognosisProtein StabilityCCND1 protein, humanCDK4 protein, humanCDK6 protein, humanCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6biochemistryCDK4CDK6cell proliferationchemical biologycullin-RING ligasescyclin D1human

Identifiers

PMID40272409
PMCPMC12021411

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.